Elizabeth Trehu
M.D.
immunology
avid biotics
Bahamas
Biography
Elizabeth Trehu, M.D., brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and implementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier, held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Prior to that, she was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program.
Research Interest
Elizabeth Trehu, M.D., brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and implementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier, held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Prior to that, she was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program.
